Connor, Clark & Lunn Investment Management (CC&L)’s Harvard Bioscience HBIO Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-200,032
| Closed | -$422K | – | 1501 |
|
|
2024
Q4 | $422K | Buy |
200,032
+20,026
| +11% | +$42.3K | ﹤0.01% | 1186 |
|
|
2024
Q3 | $484K | Buy |
180,006
+29,607
| +20% | +$79.6K | ﹤0.01% | 1104 |
|
|
2024
Q2 | $429K | Buy |
150,399
+6,344
| +4% | +$18.1K | ﹤0.01% | 1089 |
|
|
2024
Q1 | $611K | Buy |
144,055
+2,566
| +2% | +$10.9K | ﹤0.01% | 1049 |
|
|
2023
Q4 | $757K | Sell |
141,489
-20,330
| -13% | -$109K | ﹤0.01% | 940 |
|
|
2023
Q3 | $696K | Buy |
161,819
+63,174
| +64% | +$272K | ﹤0.01% | 937 |
|
|
2023
Q2 | $542K | Buy |
+98,645
| New | +$542K | ﹤0.01% | 969 |
|
|
2022
Q1 | – | Sell |
-54,252
| Closed | -$382K | – | 1112 |
|
|
2021
Q4 | $382K | Sell |
54,252
-15,060
| -22% | -$106K | ﹤0.01% | 855 |
|
|
2021
Q3 | $484K | Buy |
69,312
+7,749
| +13% | +$54.1K | ﹤0.01% | 777 |
|
|
2021
Q2 | $513K | Sell |
61,563
-1,137
| -2% | -$9.48K | ﹤0.01% | 783 |
|
|
2021
Q1 | $342K | Sell |
62,700
-17,349
| -22% | -$94.6K | ﹤0.01% | 843 |
|
|
2020
Q4 | $343K | Sell |
80,049
-18,174
| -19% | -$77.9K | ﹤0.01% | 767 |
|
|
2020
Q3 | $296K | Buy |
98,223
+49,423
| +101% | +$149K | ﹤0.01% | 791 |
|
|
2020
Q2 | $151K | Buy |
48,800
+3,025
| +7% | +$9.36K | ﹤0.01% | 924 |
|
|
2020
Q1 | $101K | Buy |
45,775
+4,575
| +11% | +$10.1K | ﹤0.01% | 931 |
|
|
2019
Q4 | $126K | Sell |
41,200
-500
| -1% | -$1.53K | ﹤0.01% | 867 |
|
|
2019
Q3 | $128K | Buy |
+41,700
| New | +$128K | ﹤0.01% | 892 |
|
|
2015
Q1 | – | Sell |
-12,800
| Closed | -$73K | – | 589 |
|
|
2014
Q4 | $73K | Buy |
12,800
+700
| +6% | +$3.99K | ﹤0.01% | 556 |
|
|
2014
Q3 | $49K | Buy |
+12,100
| New | +$49K | ﹤0.01% | 535 |
|